Risk factors
Akebia Therapeutics (AKBA) risk factors
Item 1A of every Akebia Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors109 risks21 new11 dropped69 reworded
Akebia faces financing and Going Concern risks tied to Vafseo revenue projections and cash reserves.
Filed Feb 26, 2026 - FY2024 10-K risk factors99 risks
Akebia Therapeutics faces significant financial risks centered on the ongoing commercialization and profitability of its core products, Auryxia and Vafseo. The company relies heavily on debt facilities with restrictive covenants, such as the BlackRock credit agreement, and depends on favorable reimbursement policies and successful clinical and regulatory execution.
Filed Mar 13, 2025